Q4 FY2025 · Press release
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients · January 26, 2026 · 4 pages
Read Sarepta Therapeutics, Inc.'s results firsthand
Preview the first 2 pages of this press release
Create a free account to start reading
Full documents are included with Professional